Search

Displaying results 6441 - 6450 of 8010 in total
  1. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval.

  2. Drug

    Pirisudanol

    go.drugbank.com/drugs/DB13412
    Experimental

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  3. Drug

    Zalutumumab

    go.drugbank.com/drugs/DB12202
    Investigational

    Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.

  4. Drug

    Metisazone

    go.drugbank.com/drugs/DB13641
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Lascufloxacin

    go.drugbank.com/drugs/DB20002
    Experimental

    Lascufloxacin is a small molecule drug. The usage of the INN stem '-oxacin' in the name indicates that Lascufloxacin is a nalidixic acid derivative antibacterial. Lascufloxacin has a monoisotopic molecular weight of 439.17 Da.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  7. Drug

    Sodium borate

    go.drugbank.com/drugs/DB14505
    Approved

  8. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...

  9. Drug

    Pyrrobutamine

    go.drugbank.com/drugs/DB13846
    Experimental

    Categories: Antihistamines for Systemic Use
  10. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes. … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.